

## IN THE CLAIMS

### Claims 1-270 (canceled)

271. **(currently amended)** A method of treating ~~or preventing~~ an ophthalmologic disorder characterized by an accumulation of retinotoxic compounds in the cells of the retinal pigment epithelium in a subject comprising administering to [[a]] the subject a pharmaceutically acceptable amount of fenretinide or a pharmaceutically acceptable salt thereof.
272. **(previously presented)** The method of claim 271, wherein fenretinide inhibits, antagonizes, or short-circuits the visual cycle at a step of the visual cycle that occurs outside a disc of a rod photoreceptor cell.
273. **(previously presented)** The method of claim 271, wherein the ophthalmologic disorder is macular degeneration.
274. **(withdrawn)** The method of claim 271, wherein the ophthalmologic disorder is Stargardt's disease.
275. **(withdrawn)** The method of claim 271, wherein the ophthalmologic disorder is lipofuscin accumulation.
276. **(previously presented)** The method of claim 271, wherein fenretinide increases the rate at which 11-*cis*-retinal is isomerized to all-*trans*-retinal; inhibits, antagonizes, or short-circuits the visual cycle in the retinal pigment epithelium; inhibits at least one of lecithin retinol acyl transferase, isomerohydrolase, and 11-*cis*-retinol dehydrogenase, or inhibits binding to RPE65.

### Claims 277-279 (canceled)